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ABSTRACT 
 
Aims: Our objective was to explore the use of codeine analgesics in individual patients in Norway, giving 
special attention to the 10% who consume the highest amounts. 
Methods: We retrieved data from the Norwegian Prescription Database on patients who were dispensed at 
least one codeine analgesic prescription during 2006. We looked at age and gender specific 1-year periodic 
prevalence. The 10% of codeine users who were prescribed the highest amounts of the drug that year were 
further characterized. Age and gender distribution and concurrent high consumption of other potential 
drugs of abuse were also considered. 
Results: In the year 2006, a total of 386,836 individuals filled at least one prescription for codeine analge-
sics from Norwegian pharmacies, excluding cancer patients. The crude prevalence for the use of codeine 
analgesics was 7.3% and 9.3% of the male and female Norwegian population, respectively. Twelve percent 
of women and 9% of men who filled a codeine prescription received 120 defined daily doses (DDD) or 
more of codeine analgesics in 2006 (moderate to high consumers). Fifty percent of those patients (21,759) 
were also dispensed large amounts of benzodiazepines or carisoprodol over the same period. In compari-
son, only ten percent of patients who received fewer than 120 DDD of codeine analgesics were dispensed 
large amounts of benzodiazepines or carisoprodol. 
Conclusions: A high percentage of the Norwegian population used codeine analgesics. One-year preva-
lence use of codeine increased with age and was higher for women at all ages. Our study showed that 
codeine use was mainly sporadic, but that a relatively large sub-group of users were dispensed repeated 
prescriptions of the drug in combination with other potential drugs of abuse. 
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BACKGROUND 
 
Codeine is an opiate used for the treatment of mild to 
moderate pain. 
 There are large variations between European coun-
tries in the quantity and type of opioids used (1,2). 
Drug sale statistics show that Norway has a high con-
sumption of both codeine and morphine, while the 
sales of tramadol are low compared to the other Nor-
dic countries (3). These variations may be explained 
by differences in national treatment guidelines and 
drug reimbursement systems. 
 Fixed combinations of analgesics containing 
codeine and paracetamol (acetaminophen) are widely 
prescribed in Norway (4). The use of these analgesics 
is more common in Norway than in other European 
countries (1-3), and accounts for more than 99% of the 
overall codeine consumption in the country. 
 The number of users of a given drug cannot be cal-
culated from traditional wholesale data. Therapies may 
be used intermittently, duration of treatment may differ 
and dosing may differ from the defined daily dose 
(DDD). Further, drug use will not be evenly distribu-
ted for age or gender in the population. These limita-
tions to the use of wholesale statistics in pharmaco-
epidemiology may be especially true when applied to 
an opioid analgesic because of the wide range of 
possible therapeutic doses. 
 The Norwegian Prescription Database (NorPD) 
covers the whole of Norway. NorPD makes it possible 
to calculate prevalence and to trace the prescription 
history of individual users and describe drug use by 
epidemiological parameters (5). 
 Despite the high use of analgesics containing code-
ine in Norway, and despite the fact that codeine, as all 
opioids, has abuse potential, only a limited number of 
studies have analyzed the prescription of these drugs 
(6-9). Codeine consumption in Norway is highly 
skewed, with a small group of patients receiving large 
amounts of the drug. An earlier study has shown that 
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1% of codeine users were prescribed as much as 16% 
of the total amount of codeine dispensed (6). In 
pharmacoepidemiology, skewness of consumption has 
been used to identify drugs with abuse potential (10). 
 In this study, we wanted to explore the age and 
gender distribution and the prevalence of users of 
analgesics containing codeine in Norway. Our analy-
sis further focused on prevalence and population cha-
racteristics of the 10% of users of codeine who were 
prescribed the highest amounts of the drug, referred to 
below as “moderate/high users”. Specifically we con-
sidered the group of moderate/high users for possible 
concurrent use of large amounts of other potential 
drugs of abuse. 
 
 
MATERIAL AND METHODS 
 
Source of data 
 
Data was drawn from NorPD. From 1st January 2004, 
all pharmacies in Norway are obliged to submit data 
electronically to the Norwegian Institute of Public 
Health on all dispensed prescriptions. This is done on 
a monthly basis. NorPD contains information on all 
prescription drugs, reimbursed or not, which are dis-
pensed at pharmacies to individual patients outside 
institutions. Each record should contain a unique 
person-identifier, which makes it possible to identify 
chronologically all prescriptions by the individual 
patient and by the prescribing physician. Prescription 
data is collected from pharmacies, and so only cap-
tures prescriptions that are actually dispensed. The 
reimbursement code is also recorded and may be used 
as a proxy for diagnosis. 
 All medicines in Norway are classified according 
to the ATC classification system (11). Products 
containing codeine are included both in ATC code 
N02AA59 and in R05DA04. All analgesics in ATC 
code N02AA59 contain paracetamol and codeine and 
the majority of these combinations on the Norwegian 
market are tablets containing 30 mg codeine phos-
phate and 400 mg or 500 mg paracetamol per tablet. 
These compounds were the subject of our study. For 
the product containing 400 mg paracetamol, a DDD 
will represent 120 mg codeine and 1,600 mg paraceta-
mol. For the product containing 500 mg paracetamol, 
a DDD will represent 90 mg codeine and 1,500 mg 
paracetamol. In spite of this flaw in accuracy, DDD is 
a practical tool to describe the amount of codeine 
dispensed. We did not feel it was necessary to correct 
for this difference in codeine DDD definition for the 
two compounds, in part because the product contai-
ning 400 mg paracetamol is dominant in the market, 
and in part because the difference is of little impor-
tance for this study. A plain codeine brand containing 
only 8-10 mg codeine is classified in the ATC code 
R05DA04, but sale of this brand was not included in 
the study since it is primarily used as a cough supp-
ressant and constitutes only 0.6% of total sales of 
codeine in Norway. Use of codeine analgesics by 
individuals staying in hospitals and nursing homes, or 
codeine compounds sold as supplies to physician 
offices, amounted to 8.3% of the total DDD sold in 
Norway and was not a part of this analysis. 
 
Study population  
We identified all users of codeine compounds recor-
ded in the NorPD during 2006. Patients with incom-
plete person-identifiers represented 1.9% of the pre-
scriptions of codeine compounds and were excluded 
from further analysis. Subjects who presented one or 
more codeine prescriptions but who had the reim-
bursement code for cancer were also excluded. 
 Moderate/high users of codeine analgesics were 
defined as the 10% of codeine users prescribed the 
highest amount of DDD in 2006. To explore possible 
concurrent use of other potential drugs of abuse, we 
identified individuals who filled prescriptions for ben-
zodiazepines and carisoprodol (a muscle relaxant with 
recognized abuse potential, often used together with 
benzodiazepines) in 2006 (12). High consumers of 
benzodiazepines and carisoprodol were identified as 
those who received 100 DDD or more and 15 DDD or 
more in 2006, respectively, as previously defined by 
others (6). 
 The concurrent drugs we studied were benzodiaze-
pine anxiolytics marketed in Norway (ATC N05BA): 
diazepam, oxazepam, alprazolam; benzodiazepine 
hypnotics (ATC N05CD): nitrazepam, flunitrazepam, 
midazolam; and the centrally acting muscle relaxant 
agent carisoprodol (ATC M03BA02). 
 
Statistical methods  
Age and gender specific 1-year periodic prevalence 
was estimated by dividing the number of patients who 
had filled at least one prescription for codeine com-
pounds in 2006 by the total number of persons in 
Norway in this age group on January 2006 . 
    Age and gender distribution of the Norwegian 
population in January 2006 were obtained from Sta-
tistics Norway (13). 
    Analyses were done using SPSS 14.0 for Windows. 
 
 
RESULTS 
 
Users of codeine analgesics  
In the year 2006, a total of 386,836 individuals with a 
valid person identifier filled at least one prescription 
for codeine compounds from Norwegian pharmacies, 
excluding cancer patients. Of these, 44% were males 
(169,501), yielding a crude prevalence for the use of 
codeine analgesics of 7.3% and 9.3% of the male and 
female Norwegian population, respectively. The 1-
year prevalence for different age groups is shown in 
figure 1. Prevalence increased with age for both gen-
ders, and was around 20% higher for females than for 
males. 
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Figure 1.  Gender and age specific 1 year periodic prevalence for individuals dispensed at least one codeine 
prescription in a Norwegian pharmacy in 2006. 
 
 
 
 The amount of drug received per patient varied 
widely (figure 2). Approximately 40% of the users re-
ceived fewer than 12 DDD per year and 75% received 
fewer than 50 DDD per year. The 10% of users 
receiving the highest amounts of drug, received 120 
DDD or more per year. Ten individuals were pre-
scribed amounts over 2,000 DDD. 
 
Moderate/high users of codeine analgesics 
 
Moderate/high users of codeine analgesics were 
defined as the 10% of users who received the highest 
amounts of the drug in 2006, corresponding to 120 
DDD or more. That would represent, for example, 3-4 
tablets daily (the recommended dose for acute pain) 
for 4 months or more, or the use of 1 tablet or more a 
day throughout the year. Approximately 9% (15,225) 
of males and 12% (26,234) of females who filled a  
 
 
Figure 2.  Amount of codeine prescribed to each patient 
in number of defined daily doses (DDD) prescribed that 
year, grouped into five categories. The pie chart shows 
the percentage of all codeine users in each group, for 
each gender. 
prescription for codeine that year received 120 DDD 
or more. The mean (median) age amongst these mode-
rate/high users was 58 (57) years for males and 62 (61) 
years for females, while patients who received fewer 
than 120 DDD codeine that year were younger. Here, 
the mean (median) age was 50 (51) for males and 54 
(54) for females. Age and gender distribution of 
moderate/high users is described in figure 3. 
 Among moderate/high users of codeine, 42% had 
been prescribed high amounts of benzodiazepines or 
carisoprodol in the same period and 8% had been 
prescribed high amounts of both benzodiazepines and 
carisoprodol (figure 4). In contrast, only 10% of 
patients who received fewer than 120 DDD of codeine 
compounds were dispensed high amounts of benzo-
diazepines or carisoprodol or both. The percentage of 
codeine users prescribed high amounts of benzo-
diazepines, carisoprodol or both increased with the 
number of DDD of codeine prescribed up to 120 DDD 
(table 1). 
 Splitting DDD groups in the range above 120 DDD 
showed a similar age/gender distribution and a similar 
percentage of patients with concurrent high use benzo-
diazepines or carisoprodol as the group of 120 DDD 
and above as a whole. 
 The frequency of moderate/high consumers of 
codeine with concurrent high use of benzodiazepines 
and/or carisoprodol was in the range of 6.9-8.1% 
(females) and 4.0-5.7% (males) of all codeine users for 
the different age groups. 
 
 
DISCUSSION 
 
A high percentage of the Norwegian population (~8%) 
filled a prescription of codeine analgesics at least once 
during 2006. One-year prevalence use of codeine 
increased with age for both genders and was higher for 
women than for men at all ages above 10 years, rea-
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Figure 3.  Age and gender distribution of patients dispensed codeine using under or above 120 
defined daily doses (DDD) of codeine per year. 
 
 
 
Figure 4.  Concurrent use of ≥ 100 defined daily doses (DDD) benzodiazepines and/or ≥15 DDD 
carisoprodol among those who use less than 120 DDD or more of codeine analgesics respectively. 
 
 
 
ching 20% for women older than 80 years. The 10% of 
users receiving the highest amount of the drugs in 
2006 received 120 DDD or more. The prevalence of 
users receiving 120 DDD or more of codeine in the 
general population increased with age to a maximum 
of 3.2 and 1.7 per hundred inhabitants for females and 
males over 80 years, respectively. Fifty percent of 
those patients (21,759) were dispensed large amounts 
of benzodiazepines or carisoprodol over the same 
period. In comparison, 10% of patients who received 
fewer than 120 DDD of codeine analgesics were 
dispensed large amounts of benzodiazepines or 
carisoprodol. 
 The distribution of the amount of codeine prescri-
bed to each individual per year was highly skewed. A 
previous study plotted a Lorenz curve for DDDs of 
codeine sold in 2004 and showed that 1% of codeine 
users were prescribed 16% of the total amount of co-
deine prescribed that year (6). While most users have 
a sporadic use of the drug, a substantial percentage of 
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Table 1.  Distribution of codeine users by amount of codeine received, plotted against concurrently dispensed 
amount of benzodiazepines and carisoprodol in the same year. Amounts in defined daily doses (DDD). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
users received high amounts. The highest amount we 
found was over 10 times the recommended daily dose 
every day of the year. 
 In this study, a moderate/high consumer was 
defined as a person who received 120 DDD or more 
during the year as this was the amount consumed by 
the 10% of patients with the highest consumption. A 
consumption of 120 DDD of codeine per year is not 
high in itself. It can represent, for example, the use of 
3-4 tablets daily (the recommended dose for acute 
pain) for 4 months or more or the use of 1 tablet a day 
throughout the year. However, this amount does 
reflect repeated prescribing. Long term use of opioids 
for chronic non-malignant pain is not well documen-
ted. Norway’s national guidelines advise a restrictive 
approach and careful assessment of pain relief versus 
unwanted effects in long term use (14). It is difficult 
to establish limits for “high” use of codeine analgesics 
as codeine compounds are largely prescribed to treat 
unspecified joint or muscle pain (15), which are not 
well defined diagnostically. Drug abuse is even more 
difficult to identify. A recent paper tried to identify 
pharmacoepidemiological parameters that can diffe-
rentiate drugs of abuse from drugs without abuse 
potential. Skewness in the distribution of the drug 
prescribed to each individual per year was one of the 
signs that could differentiate drugs of abuse from ot-
her drugs without abuse potential (10). Prevalence of 
use and DDD distribution in our material was highly 
coincident with the results from a previous study of 
codeine prescriptions from a Norwegian county in 
1994, suggesting a stable consumption profile over 
this time period. 
 Codeine may be associated with a lower addiction 
potential than, for example, morphine even though 
codeine use among multi-drug abusers is frequent 
(16,17). Our study showed that codeine use was 
mainly sporadic, but that a relatively large sub-group 
of users received repeated dispensation of the drug. 
Whether this represented opioid abuse or chronic the-
rapeutic analgesic use was not possible to determine. 
The high concurrent use of other drugs with abuse po-
tential, benzodiazepines and carisoprodol, in quantities 
above therapeutic recommendations among the mode-
rate/high users of codeine can suggest the possibility 
of drug abuse. It is noteworthy that increasing consum-
ption of codeine analgesics, even in the range below 
120 DDD, is also associated with use of high amounts 
of benzodiazepines/carisoprodol, in our material. The 
percentage of patients with concurrent use of high 
amounts of benzodiazepines or carisoprodol did not 
further increase with dispensation of DDD above 120 
DDD per year. 
 We acknowledge that complex and multi-sympto-
matic conditions in clinical practice may require drug 
use that does not fit therapeutic guidelines. Neverthe-
less, a subgroup of subjects who are receiving more 
than 365 DDD and up to several thousand DDD per 
year may be suggestive of drug abusers and is strong-
ly suggestive of the diversion of codeine analgesics to 
the illegal market, as the personal ingestion of such 
large amounts of paracetamol would represent a high 
risk of liver damage. 
 
 
CONCLUSION 
 
A high percentage of the Norwegian population used 
codeine analgesics. One-year prevalence use of code-
ine increased with age and was higher for women at 
all ages. Ten percent of codeine users were prescribed 
120 DDD or more in 2006. Approximately 50% of 
those were concurrently prescribed high amounts of 
benzodiazepines and/or carisoprodol. 
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 Concurrent use of 
benzodiazepines or carisoprodol N (%) 
DDD of codeine 
analgesics in 2006 N 
Amount of 
benzodiazepines  
0-99 DDD 
and carisoprodol 
0-14 DDD 
Amount of 
benzodiazepines  
≥ 100 DDD 
or carisoprodol 
≥ 15 DDD 
Amount of 
benzodiazepines  
≥ 100 DDD 
and carisoprodol 
≥ 15 DDD 
< 12 1666353 158695 (95.4%) 7126 (4.3%)  532 (0.3%) 
12-24     86115  78954 (91.7%) 6690 (7.8%) 471 (0.5%) 
25-49     51688 44109 (85.3%) 7046 (13.6%) 533 (1.0%) 
50-119     41221 30638 (74.3%) 9711 (23.6%) 872 (2.1%) 
≥ 120     41459 20700 (49.9%) 17379 (41.2%) 3380 (8.2%) 
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